MedTrace Logo

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

NCT05384821 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-03-18

No results posted yet for this study

Summary

This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy.

Conditions

  • Wilms Tumor

Interventions

DRUG

Vincristine

IV, D1-D22-D43 and D64

DRUG

Irinotecan

Oral, 5 days/week during W1,W2,W7 and W8 (D1 to D5, D8 to D12, D43 to D47, D50 to D54)

DRUG

Temozolomide

Oral,3 weeks in a row, twice per cycle (D1 to D21, D43 to D63)

DRUG

Etoposide

Oral, 3 weeks in a row, twice per cycle (D22 to D42, D64 to D84)

DRUG

Cis-Retinoic acid

Oral, 2 weeks in a row, thrice per cycle (D15 to D28, D43 to D56, D71 to D84)

Sponsors & Collaborators

  • Centre Oscar Lambret

    lead OTHER

Principal Investigators

  • Hélène SUDOUR-BONNANGE, MD · Centre Oscar Lambret

  • Arnauld VERSCHUUR, MD, PhD · CHU La Timone

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Months
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-14
Primary Completion
2028-05-31
Completion
2028-10-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05384821 on ClinicalTrials.gov